Explore

Rapid Read Rapid Read
NYU Langone's CAR T Cell Therapy Enables Kidney Transplants for Hard-to-Match Patients

NYU Langone's CAR T Cell Therapy Enables Kidney Transplants for Hard-to-Match Patients

A groundbreaking phase 1 clinical trial led by NYU Langone Health and the University of Pennsylvania has demonstrated that CAR T cell therapy can enable kidney transplants for patients with end-stage kidney disease who are difficult to match with donors. These patients, known as 'highly sensitized,' have high levels of antibodies that typically reject donor kidneys. The trial successfully reduced these antibodies, allowing three patients to receive transplants. The study, published in The New England Journal of Medicine, marks a significant advancement in transplant medicine, offering new hope to the over 91,000 Americans waiting for kidney transplants, particularly the 5,000 who are highly sensitized.
Rapid Read Rapid Read
Nephrodite's Holly System Selected for FDA's TAP to Enhance Dialysis Development

Nephrodite's Holly System Selected for FDA's TAP to Enhance Dialysis Development

Nephrodite, Inc., a medical device company, has announced that its Holly implantable continuous dialysis system has been selected to participate in the U.S. Food and Drug Administration's (FDA) Total Product Life Cycle Advisory Program (TAP). This program is designed to accelerate the development and patient access for medical devices addressing critical unmet healthcare needs. The Holly system aims to provide a continuous renal replacement therapy for patients with end-stage kidney disease, offering an alternative to the traditional three-times-weekly clinic-based dialysis. The selection into TAP follows Nephrodite's receipt of the FDA Breakthrough Device Designation in late 2025. The company is preparing for Good Laboratory Practice studies and regulatory submissions to pave the way for early feasibility trials.
Rapid Read Rapid Read
Kidney Recipient Andrew Menard Prepares for Fifth Transplant Games, Highlighting Organ Donation Impact

Kidney Recipient Andrew Menard Prepares for Fifth Transplant Games, Highlighting Organ Donation Impact

Andrew Menard, a kidney recipient and leader of Team Rocky Mountain, is preparing to compete in his fifth Transplant Games. The event, which celebrates organ donation and transplantation, provides a platform for recipients like Menard to connect with others who have undergone similar experiences. Menard has expressed gratitude for the relationships and connections he has formed through the Games. His donor, Jen Mercado, has also shared her story, emphasizing the personal impact and significance of organ donation. The Transplant Games serve as a testament to the life-changing effects of organ transplants and the community it fosters among recipients and donors.
Trendline Trendline
Qaelon Medical and Scialytics Partner to Enhance AI-Driven Surgical Intelligence in Colorectal Surgery

Qaelon Medical and Scialytics Partner to Enhance AI-Driven Surgical Intelligence in Colorectal Surgery

Qaelon Medical and Scialytics Partner to Enhance AI-Driven Surgical Intelligence in Colorectal Surgery
Trendline Trendline
OhhMed Medical Launches UK Clinical Trial for Post-Prostatectomy Recovery Using Vertica Device

OhhMed Medical Launches UK Clinical Trial for Post-Prostatectomy Recovery Using Vertica Device

OhhMed Medical Launches UK Clinical Trial for Post-Prostatectomy Recovery Using Vertica Device
Trendline Trendline
Moonlight Therapeutics Launches Phase I Trial for Peanut Allergy Treatment MOON101

Moonlight Therapeutics Launches Phase I Trial for Peanut Allergy Treatment MOON101

Moonlight Therapeutics Launches Phase I Trial for Peanut Allergy Treatment MOON101
Rapid Read Rapid Read
NYU Langone Health Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49%

NYU Langone Health Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49%

A study led by NYU Langone Health and its Perlmutter Cancer Center has demonstrated that a combination of a vaccine, intismeran, and the immunotherapy drug pembrolizumab (Keytruda) can significantly reduce the risk of melanoma recurrence and death. The phase 2b trial, known as KEYNOTE-942, involved 107 patients who had undergone melanoma surgery. The results, presented at the 2026 annual meeting of the American Society of Clinical Oncology, showed that the combination therapy reduced the risk of cancer recurrence or death by 49% compared to the standard treatment of pembrolizumab alone. Additionally, the combination therapy reduced the risk of distant metastasis by 59%. The study highlights the potential of mRNA vaccines like intismeran in enhancing the effectiveness of immunotherapy for cancers with high mutation rates.
Rapid Read Rapid Read
Study Finds GLP-1 Drugs May Reduce Breast Cancer Risk by 30%

Study Finds GLP-1 Drugs May Reduce Breast Cancer Risk by 30%

A study from the University of Pennsylvania's Perelman School of Medicine has found that women taking GLP-1 medications, commonly used for weight loss, are 30% less likely to develop breast cancer. The analysis involved over 110,000 women aged 45 to 80, revealing that these drugs, while not originally designed for cancer therapy, affect pathways associated with cancer development. The findings suggest potential for GLP-1 drugs as preventive treatments for high-risk women, although further clinical trials are needed to confirm their efficacy in cancer prevention.
Rapid Read Rapid Read
NYU Langone Health Study Shows mRNA Vaccine Reduces Melanoma Recurrence by 49%

NYU Langone Health Study Shows mRNA Vaccine Reduces Melanoma Recurrence by 49%

A recent study conducted by NYU Langone Health and its Perlmutter Cancer Center has demonstrated that a combination of an mRNA-based vaccine, intismeran, and the immunotherapy drug pembrolizumab significantly reduces the risk of melanoma recurrence and death. The study involved 107 patients who had undergone melanoma surgery and were randomly selected to receive the combination therapy. Results showed a 49% reduction in the risk of cancer recurrence or death compared to a control group receiving only pembrolizumab. The study, known as KEYNOTE-942, was presented at the American Society of Clinical Oncology's annual meeting and published in the Journal of Clinical Oncology. The vaccine works by teaching the immune system to recognize and attack cancer cells, utilizing T cells to target specific neoantigens produced by melanoma cells.
Rapid Read Rapid Read
mRNA Vaccine for Melanoma Shows Significant Efficacy in Preventing Recurrence

mRNA Vaccine for Melanoma Shows Significant Efficacy in Preventing Recurrence

A recent study has shown that a personalized mRNA vaccine, developed by Moderna in collaboration with Merck, is highly effective in preventing the recurrence of melanoma when used alongside the immunotherapy drug Keytruda. The trial, which included 157 patients from the U.S. and Australia, demonstrated that the combination therapy reduced the risk of cancer recurrence by 49% over five years. The vaccine is tailored to each patient's tumor, using mRNA technology to train the immune system to recognize and attack specific neoantigens associated with the cancer. This approach has shown promising results, with 68.8% of patients remaining cancer-free after five years, compared to 49.1% who received only Keytruda.
Rapid Read Rapid Read
NYU Langone Health Study Reveals Widening Income Disparities in Lung Cancer Survival

NYU Langone Health Study Reveals Widening Income Disparities in Lung Cancer Survival

Researchers from NYU Langone Health's Perlmutter Cancer Center presented findings at the 2026 ASCO Annual Meeting, highlighting a significant increase in the survival gap between high- and low-income counties since the introduction of lung cancer screening guidelines in 2013. The study, led by Dr. Daniel J. Becker, analyzed nearly 1 million lung cancer cases diagnosed between 2005 and 2022. It found that while lung cancer screening has improved early diagnosis and survival rates across all income groups, the benefits have been disproportionately greater in wealthier communities. This has resulted in a 12.2 percent larger survival gap in the screening era compared to the years before the guidelines were adopted.
Rapid Read Rapid Read
Personalized mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence

Personalized mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence

A clinical trial has demonstrated the potential of a personalized mRNA vaccine in reducing the recurrence of melanoma. Conducted by researchers at NYU Langone Health, the trial involved 157 patients in Australia and the U.S. who had undergone surgery to remove their tumors. The study combined the mRNA vaccine with Keytruda, an immunotherapy drug, and showed that 68.8% of patients remained cancer-free after five years, compared to 49.1% who received Keytruda alone. The results, presented at the American Society of Clinical Oncology conference, highlight the vaccine's ability to train T cells to recognize and target specific neoantigens, enhancing the immune system's response to cancer.